每月与按需玻璃体腔注射雷珠单抗治疗放射性视网膜病变相关黄斑水肿的随机试验:1年结果
这项IIb期多中心随机临床试验纳入40例放射性黄斑水肿初治患者,比较每月雷珠单抗、每月雷珠单抗联合靶向全视网膜光凝(TRP)、以及3次负荷剂量后按需(PRN)注射联合TRP三种方案。12个月时三组平均BCVA变化分别为+4.0、-1.9和+0.9字母,组间差异显著(P < .001),每月注射组视力获益最大,加用TRP未见治疗获益。
要点
- 每月雷珠单抗组12个月平均BCVA提升+4.0字母,优于联合激光组和PRN联合激光组。
- 三组间1年平均BCVA差异显著(P < .001),两两比较亦显著,每月组获益最大。
- 加用靶向全视网膜光凝未带来额外治疗获益。
核心结论
- 雷珠单抗可改善放射性视网膜病变相关黄斑水肿患者的视力和解剖结构,并在48周治疗期内防止视力丧失。
- 每月注射方案比按需(PRN)方案更有效,加用TRP未产生治疗获益。
研究设计与样本
- IIb期、前瞻性、随机临床试验,多中心设置。
- 纳入40例(40眼)放射性黄斑水肿初治患者,Snellen等效视力在20/25至20/400之间。
- 干预分为三组:每月玻璃体腔注射0.5 mg雷珠单抗、每月雷珠单抗联合TRP、3次每月负荷剂量后按需注射联合TRP;52周后所有受试者进入treat-and-extend方案。
- 主要结局指标为基线至12个月的ETDRS BCVA平均变化。
主要发现
- 患者平均年龄57岁(范围22-80岁),平均ETDRS BCVA为56.7字母(Snellen等效20/74),中心黄斑厚度(CMT)为423 μm(范围183-826 μm)。
- 三组间1年平均BCVA差异显著(P < .001),两两比较亦显著,每月组获益最大。
- 82.5%的患者保留20/200或更好视力,20.0%的患者ETDRS字母提升≥10个。
关键数值与推荐
- 每月组12个月平均BCVA变化+4.0字母;每月联合激光组-1.9字母;PRN联合激光组+0.9字母。
- 三组间1年平均BCVA差异P < .001。
- 82.5%患者保留视力≥20/200;20.0%患者提升≥10个ETDRS字母。
临床怎么用
- 对放射性视网膜病变相关黄斑水肿,每月雷珠单抗注射较按需方案更能改善视力。
- 联合靶向全视网膜光凝未显示额外获益,决策时可不依赖该联合策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess efficacy of intravitreal ranibizumab injections and targeted panretinal photocoagulation (TRP) for radiation retinopathy-related macular edema. DESIGN: Phase IIb, prospective, randomized clinical trial. METHODS: Setting: Multicenter. SUBJECTS: Forty eyes in 40 treatment-naïve patients with radiation-induced macular edema and a resulting decrease in visual acuity ranging between 20/25 and 20/400 (Snellen equivalent). INTERVENTION: Patients either received intravitreal 0.5 mg ranibizumab monthly, monthly ranibizumab with TRP, or 3 monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP. After week 52, all subjects entered a treat-and-extend protocol for ranibizumab. MainOutcomeMeasures: Mean Early Treatment Diabetic Maculopathy Study (ETDRS) BCVA change from baseline. RESULTS: Mean patient age was 57 years (range, 22-80 years), ETDRS BCVA was 56.7 letters (20/74 Snellen equivalent), and central macular thickness (CMT) was 423 μm (range, 183-826 μm). Thirty-seven patients completed the month 12 visit (92.5%), at which time the change in mean BCVA was +4.0 letters, -1.9 letters, and +0.9 letters in the monthly, monthly plus laser, and PRN plus laser cohorts, respectively. There was a significant difference in mean BCVA at 1 year among all 3 cohorts (P < .001), as well as between cohorts in pairwise comparisons, with the most significant gains in the monthly group. A total of 82.5% of the patients retained visual acuity of 20/200 or better, and 20.0% improved 10 or more ETDRS letters. CONCLUSIONS: Ranibizumab may improve vision and anatomy in patients with radiation retinopathy-related macular edema and prevent vision loss through 48 weeks of therapy. Monthly injections were more effective than as-needed approach, and the addition of TRP yielded no therapeutic benefits.
引用
- Schefler AC, Fuller D, Anand R, et al. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes. Am J Ophthalmol. 2020. PMID: 32278771. doi:10.1016/j.ajo.2020.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。